Boehringer
1,100 jobs to go as Ben Venue confirms closure of Bedford unit
October 7, 2013Manufacturing and Production, Sales and Marketing Ben Venue, Boehringer, FDA
Boehringer Ingelheim is calling time on its troubled facility in Ohio operated by Ben Venue Laboratories and says it will …
Boehringer cancer drug impresses
October 1, 2013Research and Development, Sales and Marketing Boehringer, NSCLC, nintedanib
Boehringer Ingelheim has shown off its impressive oncology treatment nintedanib at the European Cancer Congress (ECC) in Amsterdam. The oral triple …
Boehringer cuts ribbon on €70m addition to Shanghai plant
September 27, 2013Manufacturing and Production, Sales and Marketing Boehringer, China, Shanghai
Boehringer Ingelheim has officially opened the €70 million expansion of its facility in Zhangjiang, China, that is designed to triple …
Boehringer and Ventana link up
September 24, 2013Research and Development, Sales and Marketing Boehringer, Ventana, oncology
Boehringer Ingelheim has signed a deal with Roche subsidiary Ventana Medical Systems to develop companion diagnostic tests for Boehringer’s oncology …
Boehringer to shut down Petersburg chemicals facility
August 16, 2013Manufacturing and Production, Sales and Marketing Boehringer, Petersburg
Boehringer Ingelheim has conceded defeat in its search for a buyer for its chemicals facility in Petersburg, US, and is …
Boehringer nears European approval for first cancer drug
July 29, 2013Sales and Marketing Boehringer, Cancer, FDA, afatinib
Boehringer’s first cancer drug is just months away from being approved in Europe after a committee for the EMA gave …
Boehringer and partners launch digital diabetes study
July 19, 2013Medical Communications Boehringer, Syrum, Twitter, diabetes, digital, type 2
Boehringer Ingelheim has partnered with Healthrageous and United BioSource to establish a new diabetes study to help patients manage their …
FDA approves Boehringer’s lung cancer drug
July 12, 2013Medical Communications, Sales and Marketing Boehringer, FDA, Roche, Tarceva, afatinib, lung cancer
Boehringer Ingelheim’s late-stage lung cancer drug Gilotrif has received an accelerated FDA approval for patients with a certain genetic mutation. …
FDA has Xarelto concerns
July 2, 2013Sales and Marketing Bayer, Boehringer, FDA, Pradaxa, Xarelto
The FDA is unsure about an application to further extend the licence for Janssen and Bayer HealthCare’s blood thinner Xarelto …
NSCLC lift for Boehringer
June 4, 2013Research and Development, Sales and Marketing Boehringer, NSCLC
Boehringer’s pipeline has been boosted with the news that its investigational oral triple angiokinase inhibitor nintedanib plus chemotherapy, extends the …
Wireless pill bottle wins Boehringer challenge
May 29, 2013Medical Communications Boehringer, brett wells, wireless
Developers of a pill bottle that wirelessly measures medication and sends patient reminders have emerged as prize-winners in a Healthcare …
Boehringer held up by FDA for production violations
May 24, 2013Manufacturing and Production API, Boehringer, FDA
Boehringer Ingelheim has pledged to resolve manufacturing compliance issues at a facility in Germany uncovered by the US Food and …
Board changes at Boehringer Ingelheim
May 22, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer, baiker
Boehringer’s Professor Wolfram Carius is stepping down from the Board to be replaced by Dr Wolfgang Baiker. Carius who is …
Boehringer and OBT in cancer tie-up
May 2, 2013Research and Development, Sales and Marketing Boehringer, Cancer, OBT
Boehringer Ingelheim and UK biotech firm Oxford BioTherapeutics (OBT) have signed a deal to discover novel antibody targets in cancer. …
Boehringer’s online PMCPA breach
April 25, 2013Medical Communications, Research and Development, Sales and Marketing ABPI, AF, Boehringer, PMCPA
Boehringer Ingelheim has failed to uphold high standards, according to the PMCPA, which enforces the ABPI Code of Practice, over …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
AI: an early warning system for patient safety
Highlighting the value of lab research for healthcare innovation
